ArticleInfection and drug resistance2026
Population Pharmacokinetics and Exposure-Response Analysis of Voriconazole in ICU and Non-ICU Hospitalized Adults.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Voriconazole has marked pharmacokinetic variability and a narrow therapeutic window, making individualized dosing difficult. Published population pharmacokinetic (PopPK) models most derive from ICU or general-ward patients, and exposure-response studies are limited. This retrospective study aimed to characterize voriconazole PopPK and exposure-response analysis in real‑world hospitalized patients containing both ICU and non-ICU patients. Methods: Adults receiving voriconazole with therapeutic drug monitoring were included. PopPK analysis used NONMEM. Demographic variables and lab biomarkers were screened. Monte Carlo simulations were used to show covariates' effect on drug exposure under standard dosing regimen. Model-derived voriconazole exposure was linked to treatment outcome and adverse drug reactions (ADR) using logistic regression. Results: 292 patients with 473 voriconazole concentrations were included. A one-compartment model with first-order elimination adequately described the data, with estimated population clearance, volume of distribution and derived half-life of 3.3 L/h, 92 L and 19 h, respectively. Voriconazole clearance increased with body weight and albumin and decreased with age, CRP, total bilirubin, and serum creatinine. These covariates decrease clearance inter-individual variability from 44.5% to 32.6 %; all parameters fell within bootstrap 90% interval. With a standard regimen 300 mg every 12 h for first day then 200 mg every 12 h, simulations showed underexposure in younger patients without organ dysfunction and overexposure in elderly patients with elevated CRP, total bilirubin or serum creatinine. In multivariable logistic regression, excessively high average concentration (Cavg) derived by model was associated with treatment failure (adjusted odds ratio 1.45 per mg/L, 95% CI 1.07-2.03, p=0.019). Cavg was not significant, whereas older age was associated with higher ADR risk (adjusted odds ratio 1.05, 95% CI 1.01-1.10). Conclusion: Age, CRP, albumin, total bilirubin and creatinine explain clinically relevant variability in voriconazole exposure and indicate that a fixed regimen may not benefit all patients. The association between higher Cavg and treatment failure is observational and needs further prospective studies and external validations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.